Literature DB >> 29285508

Semaglutide-the "new kid on the block" in the field of glucagon-like peptide-1 receptor agonists?

Cristian Guja1,2, Rucsandra Dănciulescu Miulescu1,2.   

Abstract

Entities:  

Year:  2017        PMID： 29285508      PMCID： PMC5733318          DOI： 10.21037/atm.2017.10.09

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  21 in total

1.  Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).

Authors:  Guillermo Umpierrez; Santiago Tofé Povedano; Federico Pérez Manghi; Linda Shurzinske; Valeria Pechtner
Journal:  Diabetes Care       Date:  2014-05-19       Impact factor: 19.112

2.  A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes.

Authors:  Michael A Nauck; John R Petrie; Giorgio Sesti; Edoardo Mannucci; Jean-Pierre Courrèges; Marie L Lindegaard; Christine B Jensen; Stephen L Atkin
Journal:  Diabetes Care       Date:  2015-09-10       Impact factor: 19.112

Review 3.  Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity.

Authors:  Martin Lorenz; Andreas Evers; Michael Wagner
Journal:  Bioorg Med Chem Lett       Date:  2013-05-16       Impact factor: 2.823

4.  Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews
Journal:  Diabetes Care       Date:  2015-01       Impact factor: 19.112

Review 5.  GLP-1 receptor agonists: a review of head-to-head clinical studies.

Authors:  Jennifer M Trujillo; Wesley Nuffer; Samuel L Ellis
Journal:  Ther Adv Endocrinol Metab       Date:  2015-02       Impact factor: 3.565

6.  Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.

Authors:  Alan Garber; Robert Henry; Robert Ratner; Pedro A Garcia-Hernandez; Hiromi Rodriguez-Pattzi; Israel Olvera-Alvarez; Paula M Hale; Milan Zdravkovic; Bruce Bode
Journal:  Lancet       Date:  2008-09-24       Impact factor: 79.321

7.  Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.

Authors:  Jesper Lau; Paw Bloch; Lauge Schäffer; Ingrid Pettersson; Jane Spetzler; Jacob Kofoed; Kjeld Madsen; Lotte Bjerre Knudsen; James McGuire; Dorte Bjerre Steensgaard; Holger Martin Strauss; Dorte X Gram; Sanne Møller Knudsen; Flemming Seier Nielsen; Peter Thygesen; Steffen Reedtz-Runge; Thomas Kruse
Journal:  J Med Chem       Date:  2015-09-11       Impact factor: 7.446

8.  Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.

Authors:  David Russell-Jones; Robert M Cuddihy; Markolf Hanefeld; Ajay Kumar; Jose G González; Melanie Chan; Anne M Wolka; Marilyn K Boardman
Journal:  Diabetes Care       Date:  2011-12-30       Impact factor: 19.112

9.  Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes.

Authors:  Jennifer S ten Kulve; Dick J Veltman; Liselotte van Bloemendaal; Frederik Barkhof; Carolyn F Deacon; Jens J Holst; Robert J Konrad; John H Sloan; Madeleine L Drent; Michaela Diamant; Richard G IJzerman
Journal:  Diabetologia       Date:  2015-09-18       Impact factor: 10.122

10.  Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.

Authors:  Michael A Nauck; Murray W Stewart; Christopher Perkins; Angela Jones-Leone; Fred Yang; Caroline Perry; Rickey R Reinhardt; Marc Rendell
Journal:  Diabetologia       Date:  2015-11-17       Impact factor: 10.122
View more
  2 in total

Review 1.  Systematic Review of Efficacy and Safety of Newer Antidiabetic Drugs Approved from 2013 to 2017 in Controlling HbA1c in Diabetes Patients.

Authors:  Sivanandy Palanisamy; Emily Lau Hie Yien; Ling Wen Shi; Low Yi Si; See Hui Qi; Laura Soon Cheau Ling; Teng Wai Lun; Yap Nee Chen
Journal:  Pharmacy (Basel)       Date:  2018-06-27

Review 2.  GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data.

Authors:  Andrei C Sposito; Otávio Berwanger; Luiz Sérgio F de Carvalho; José Francisco Kerr Saraiva
Journal:  Cardiovasc Diabetol       Date:  2018-12-13       Impact factor: 9.951
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.